MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Firm”), a professional phase pharmaceutical firm devoted to prolonging healthy and balanced lifespan, today introduced that the initial individual has been registered in the Firm’s Stage 2 medical test of lead candidate MYMD-1, an oral immune regulator medicine, as a therapy for delaying aging and also expanding healthy lifespan.
The main endpoint for the Phase 2 double-blind, placebo-controlled scientific trial is to attain a decrease in the distributing levels of (TNF-α), lump death variable receptor I (TNFRI) and IL-6. TNF-α as well as IL-6 are the proteins in the body that trigger swelling and also assist activate the procedure of aging. The second steps of the test will be the safety, tolerability, as well as pharmacokinetics in this population of patients.
” In a Stage 1 scientific test of MYMD-1, we showed the medication’s statistically significant efficiency in lowering degrees of TNF-α, a key player in creating pathological aging, in the blood. The FDA has actually accepted TNF-α decrease as the main endpoint for our Stage 2 research study, which our team believe positions us well for a successful Phase 2 end result,” stated Chris Chapman, M.D., Head Of State, Director as well as Principal Medical Policeman of MyMD. “The initiation of person enrollment in this study breakthroughs our mission to reduce the aging procedure, prevent loss of muscle tissue in aging, limitation frailty, and also extend healthy and balanced life-span.”
MyMD has mentioned that there are no FDA-approved drugs for dealing with aging disorders and also expanding healthy life expectancy people, a market expected to be at least $600 billion by 20251 according to a significant investment financial institution. TNF-α blockers are one of the most proposed drugs by revenue, a global market of roughly $40 billion each year,2 and also, according to Nature Aging journal,3 a downturn in maturing that would boost life span by one year is worth $38 trillion and also by one decade is worth $367 trillion.
Along with aging, MYMD-1’s distinct activity in managing the immune system and also dealing with chronic swelling is being established for the treatment of autoimmune condition, including rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetes, and also inflammatory bowel disease.
” We mean to start creating methods for a Stage 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The rising occurrence of rheumatoid arthritis as well as various other autoimmune as well as inflammatory illness are driving demand for TNF inhibitors like MYMD-1, as well as we believe our orally carried out medicine with very reduced toxicity would be turbulent to the $60 billion market for RA if accepted by the FDA for this indicator.”
Rheumatoid arthritis affects about 40 million people worldwide.4.
Initially developed for autoimmune conditions, MYMD-1’s primary objective is to slow down the aging process, protect against sarcopenia and also frailty, and also expand healthy life expectancy. Because it can cross the blood-brain obstacle as well as gain access to the central nerve system (CNS), MYMD-1 is likewise placed to be a possible treatment for brain-related problems. Its mechanism of activity and also efficiency in illness including multiple sclerosis (MS) and also thyroiditis have been researched via partnerships with a number of academic organizations. MYMD-1 is also showing promise in pre-clinical research studies as a possible therapy for blog post- COVID-19 complications and also as an anti-fibrotic and also anti-proliferation healing.
MYMD-1 has actually revealed effectiveness in pre-clinical researches in controling the immune system by executing as a careful prevention of lump necrosis factor-alpha (TNF-α), a vehicle driver of persistent inflammation. Unlike various other treatments, MYMD-1 has actually been shown in these pre-clinical studies to uniquely block TNF-α when it ends up being overactivated in autoimmune illness and also cytokine tornados, yet not obstruct it from doing its typical work of being a first responder to any routine sort of modest infection. MYMD-1’s ease of oral dosing is one more differentiator contrasted to currently readily available TNF-α blockers, all of which call for distribution by injection or mixture. No accepted TNF inhibitor has ever before been dosed orally. Additionally, the medication is not immunosuppressive and has not been shown to create the significant adverse effects common with traditional therapies that treat inflammation.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical firm committed to extending healthy and balanced lifespan, is concentrated on creating 2 unique restorative platforms that treat the sources of condition instead of just addressing the signs. MYMD-1 is a medicine platform based upon a clinical stage small molecule that controls the body immune system to manage TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to postpone aging, rise longevity, as well as deal with autoimmune illness as well as COVID-19- associated anxiety. The Business’s second drug platform, Supera-CBD, is being established to treat persistent pain, addiction as well as epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) and also is being created to resolve and also improve upon the swiftly expanding CBD market, which includes both FDA approved drugs and also CBD products not presently controlled as drugs. For additional information, go to www.mymd.com.